Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged = 70 years: a randomized study of a single dose vs. two different two-dose schedules

Julkaisu

Reference

Vesikari T, Hardt R, Rümke HC, et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged = 70 years: a randomized study of a single dose vs. two different two-dose schedules. Hum Vaccin Immunother 2013:9(4):858-864.

Julkaisutiedot

Julkaisutyyppi: Alkuperäisartikkeli.
Kansainvälinen.
Kieli: Englanti.

Teksti/tiivistelmä: https://www.ncbi.nlm.nih.gov/pubmed/23319176

Publication data

Publication type: Original scientific article.
International.
In English.

Text/summary: https://www.ncbi.nlm.nih.gov/pubmed/23319176

Tekijät

Contributors

Tampereen yliopisto

Lääketieteen laitos/virologia 1
- Timo Vesikari

University of Tampere

Medical School/Department of Virology 1
- Timo Vesikari

Tampereen yliopistollinen sairaala

Lastentautien vastuualue
- Timo Vesikari

Tampere University Hospital

Julkaisutietokanta 19.1.2016

Publications Data Base 19.1.2016